Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Background Information:
LY2835219 (Abemaciclib) is an orally available cyclin-dependent kinase (CDK) inhibitor targeting specifically the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway. It blocks retinoblastoma (Rb) protein phosphorylation in early G1 thus prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. It is currently in clinical evaluation for cancer treatment.
APIM050188: LY2835219 (ABEMACICLIB) (FREE BASE)
CAS No.: 1231929-97-7 (Free Base); 1231930-82-7 (Mesylate Salt).
Molecular Formula: C27H32F2N8 ? 0.4H2O.
Molecular Weight: 513.9 (refer to Certificate of Analysis, batch-specific).
Purity: 99.5% by HPLC.
QC: HPLC-MS, 1H-NMR, and Quantitative Elemental Analysis Report.
Solubility: Refer to Certificate of Analysis.
Storage: Refer to Certificate of Analysis.
Copyright © 2009-2022 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.